Skip to content

Opening book details…

About this Medicine article

1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types by Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; Roy, A is a Medicine article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Medicine.

Author
Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; Roy, A
Publisher
Oxford University Press; Elsevier BV (ISSN 0923-7534)
Published
2018
Language
EN
Field
Medicine (Health Sciences)

More by Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; Roy, A

Browse all works by Zhao, X; Shen, J; Gopalakrishnan, M; Feng, Y; Schmidt, B J; Statkevich, P; Kelleher, T; Rashford, M; Ivaturi, V; Gobburu, J V S; Agrawal, S; Bello, A; Roy, A